Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Coherus BioSciences, Inc. (NASDAQ:CHRSGet Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.83.

A number of analysts recently issued reports on CHRS shares. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Coherus BioSciences in a report on Friday, May 24th. Truist Financial dropped their target price on Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, May 13th.

Read Our Latest Stock Analysis on Coherus BioSciences

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. TrinityPoint Wealth LLC acquired a new position in shares of Coherus BioSciences during the 4th quarter valued at about $40,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Coherus BioSciences by 430.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,880 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 10,454 shares during the period. Baader Bank Aktiengesellschaft purchased a new stake in shares of Coherus BioSciences in the 4th quarter valued at approximately $47,000. Vontobel Holding Ltd. acquired a new stake in shares of Coherus BioSciences during the 4th quarter worth approximately $50,000. Finally, ELCO Management Co. LLC purchased a new stake in shares of Coherus BioSciences during the 3rd quarter valued at approximately $57,000. 72.82% of the stock is owned by hedge funds and other institutional investors.

Coherus BioSciences Stock Down 2.4 %

Shares of CHRS stock opened at $1.63 on Tuesday. Coherus BioSciences has a 52-week low of $1.43 and a 52-week high of $5.47. The stock has a market cap of $187.01 million, a PE ratio of -2.09 and a beta of 0.66. The business has a 50-day simple moving average of $1.95 and a 200-day simple moving average of $2.27.

Coherus BioSciences (NASDAQ:CHRSGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The business had revenue of $77.06 million during the quarter, compared to analyst estimates of $102.00 million. During the same quarter in the previous year, the company posted ($0.89) EPS. Sell-side analysts anticipate that Coherus BioSciences will post -1.14 earnings per share for the current fiscal year.

Coherus BioSciences Company Profile

(Get Free Report

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

Recommended Stories

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with's FREE daily email newsletter.